Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Saphnelo, anifrolumab-fnia
Synonyms :
anifrolumab
Class :
Interferon Antagonists
Brand Name :
Saphnelo, anifrolumab-fnia
Synonyms :
anifrolumab
Class :
Interferon Antagonists
Dosage forms & Strengths:
Adult:
Solution for Injection
300 mg/2ml
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs (DMARDS)
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs (DMARDS)
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anifrolumab
dengue vaccine efficacy will be reduced by anifrolumab
may increase the immunosuppressive effect of anti-psoriatic agents
it may enhance the adverse effects when combined with aducanumab
When mometasone furoate is used together with anifrolumab, this leads to enhanced risk or seriousness of adverse outcomes
may diminish the immunosuppressive effect of each other when combined
measles, mumps, rubella, and varicella vaccine, live 
may diminish the immunosuppressive effect of each other when combined
measles mumps and rubella vaccine, live
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
smallpox (vaccinia) vaccine, live
may diminish the immunosuppressive effect of each other when combined
may increase the risk or severity of toxic effects when combined
combining volociximab with anifrolumab may increase the chances of adverse effects
the risk of adverse effects may be increased
Actions and Spectrum:
anifrolumab is a human monoclonal antibody that targets the interleukin-1 receptor-associated kinase 4 (IRAK4) protein. IRAK4 is involved in signaling cytokines like interleukin-1β (IL-1β), critical drivers of systemic lupus erythematosus (SLE) and other autoimmune diseases.
>10%:
Bronchitis (11%)
Upper respiratory tract infection (34%)
1-10%:
Infusion-related reactions (9.4%)
Cough (5%)
Herpes zoster (6.1%)
Hypersensitivity (2.8%)
Respiratory tract infection (3.3%)
<1%:
Malignancies (0.7)
Black Box Warning:
It is essential to follow the dosage and administration instructions for the medication carefully.
Contraindication/Caution:
anifrolumab is contraindicated in patients with hypersensitivity to the active substance or excipients.
Additionally, anifrolumab may increase the risk of developing malignancies, including lymphoma. Monitor the patients for the development of malignancies, and appropriate treatment should be initiated if a malignancy is suspected.
Pregnancy consideration:
No adequate data is available regarding the risks associated with the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the secretion of the drug during pregnancy.
Pregnancy category:
Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
anifrolumab is indicated for treating adult patients with systemic lupus erythematosus (SLE) who receive standard care. Its efficacy and safety have been demonstrated in clinical trials, and it has been shown to improve symptoms of SLE and reduce the number of flares.
Pharmacodynamics:
anifrolumab targets the interleukin-1 receptor-associated kinase 4 (IRAK4) protein. IRAK4 is involved in the signaling of cytokines like interleukin-1β (IL-1β). These are the key drivers of systemic lupus erythematosus (SLE) and other autoimmune diseases.
anifrolumab binds to IRAK4, inhibiting its activity and reducing the production of IL-1β and other cytokines. This reduction in cytokine production leads to a decrease in autoimmune diseases like SLE symptoms.
Pharmacokinetics:
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body. The following parameters can describe the pharmacokinetics of anifrolumab.
Absorption
The steady state reaches by the 85th day
The accumulation ratio is 1.36 (Cmax) and 2.49 (Ctrough)
Distribution
The volume of distribution is 6.23 L
Metabolism
The drug is not metabolized in the liver.
Elimination and excretion
The renal clearance rate is 0.193 L/day
Administration:
The drug is administered as an IV solution. 2 ml of the drug is withdrawn and added to 100 ml of 0.9% NaCl. Infuse the contents for 30 minutes.
Patient information leaflet
Generic Name: anifrolumab
Pronounced: an-i-frol-ue-mab
Why do we use anifrolumab?
anifrolumab treats candidemia, esophageal candidiasis, and candida auris.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
